1) Strategy & Leadership
- STERIS reported a strong fiscal 2026, achieving record revenues of approximately $6 billion and adjusted net income exceeding $1 billion.
- The company plans to continue mid- to high single-digit organic growth and double-digit bottom line growth, supported by a strong U.S. procedure volume growth of mid-single digits.
- STERIS is focusing on capital allocation priorities, including increasing dividends, M&A investments, and share buybacks, with a new $1 billion buyback authorization in place.

2) Financial & Segment Results
- Q4 total revenue grew 7%, with constant currency organic revenue growth of 5%.
- Adjusted net income for Q4 was $278.3 million, with earnings per diluted share at $2.83, a 3% YoY increase.
- EBIT margin for Q4 was 24.2%, slightly below the previous year due to inflation and tariffs.
- Healthcare segment grew 9% as reported, driven by a 12% increase in services and 7% in consumables.
- Life Sciences and AST segments also reported growth of 9% and 10% respectively, with AST facing some headwinds due to weather-related disruptions.

3) Problems / Headwinds
- The company faced challenges from higher tariffs, which impacted margins by approximately $46 million in fiscal 2026.
- Incremental tariffs contributed to a higher effective tax rate, which is expected to rise to 25% in fiscal 2027 due to capital allocation strategies.
- AST segment experienced a slowdown in the second half of the year, particularly in Q4, attributed to severe weather and inventory management by med tech customers.

4) Operational or Product Plans
- STERIS is investing in a new sterility assurance manufacturing plant in Mentor, Ohio, expected to enhance operational efficiency and capacity.
- The company is also implementing a multi-year project to upgrade service workflows using AI technologies to improve customer experience.
- Two tuck-in acquisitions are expected to contribute approximately $45 million in revenue for fiscal 2027, enhancing the Healthcare segment's offerings.

5) Guidance & Outlook / Investor Angle
- For fiscal 2027, STERIS anticipates 7% to 8% revenue growth, with constant currency organic growth expected at 6% to 7%.
- EBIT margins are projected to expand by approximately 50 basis points, with earnings per share guidance set at $11.10 to $11.30, reflecting 9% to 11% growth YoY.
- The company is cautious about the AST segment's performance due to difficult comparisons in the first half of the year.

Bottom line: STERIS is positioned for continued growth with a strong financial foundation, strategic investments, and a commitment to shareholder returns, despite facing some headwinds from tariffs and operational challenges in specific segments.